Administer GLP-1 receptor agonists to individuals with T2DM and either existing ASCVD or those predisposed to ASCVD, as these agents have demonstrated efficacy in lowering the occurrence of stroke [37]. The gene discussed is GLP1R; the disease is Stroke.